


Catalog # 10-4659

Vorasidenib

CAS# 1644545-52-7

6-(6-Chloropyridin-2-yl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; AG-881

Lot # FBS3001



Vorasidenib is a highly potent (IC_{50} 's = 7 nM IDH2-R140Q, 0.6 nM IDH1-R132H/WT, and 0.25 nM Neurosphere TS603 IDH1-R132H), selective, and brain-penetrant inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2).¹ It led to >97% inhibition of 2-hydroxyglutarate production in mIDH1 glioma tissue. Vorasidenib significantly improved progression-free survival and delayed time to next intervention in a phase 3 glioma trial.²

- 1) Konteatis *et al.* (2020), *Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma*; ACS Med. Chem. Lett. **11** 101
- 2) Mellinghoff *et al.* (2023), *Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma*; N. Engl. J. Med. **389** 589

PHYSICAL DATA

Molecular Weight:	414.74
Molecular Formula:	C ₁₄ H ₁₃ ClF ₆ N ₆
Purity:	>98% HPLC
	NMR: Conforms
Solubility:	DMSO (25 mg/mL)
Physical Description:	White solid
Storage and Stability:	Store as supplied at -20°C for up to 2 years from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.